Monoclonal antibodies: A review

Current Clinical Pharmacology

Volumn 13, Issue 2, 2018, Pages 85-99

  Singh, Surjit ^a   Tank, Nitish K ^a   Dwiwedi, Pradeep ^a   Charan, Jaykaran ^a   Kaur, Rimplejeet ^a   Sidhu, Preeti ^a   Chugh, Vinay K ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Autoimmune; Cancer; Cytokines; Growth factors; Monoclonal antibody; Transplant

Indexed keywords

ALEMTUZUMAB; BETA INTERFERON; BETA1A INTERFERON; BLINATUMOMAB; BRENTUXIMAB VEDOTIN; CD20 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DARATUMUMAB; DEXAMETHASONE; EFALIZUMAB; ELOTUZUMAB; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GLATIRAMER; IBRITUMOMAB TIUXETAN; IPILIMUMAB; LENALIDOMIDE; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; METHOTREXATE; MONOCLONAL ANTIBODY; OBINUTUZUMAB; OFATUMUMAB; OKT 3; PREDNISOLONE; RITUXIMAB; STEROID; TOSITUMOMAB; UNINDEXED DRUG; VINCRISTINE; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOID LEUKEMIA; ANAPHYLAXIS; ANAPLASTIC LARGE CELL LYMPHOMA; ASTHMA; AUTOIMMUNE DISEASE; AUTOIMMUNE THYROIDITIS; B CELL LYMPHOMA; BREAST CANCER; CARDIOVASCULAR DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL EFFECTIVENESS; COLITIS; CYTOKINE RELEASE SYNDROME; CYTOKINE STORM; DERMATITIS; DIFFUSE LARGE B CELL LYMPHOMA; DRUG APPROVAL; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; ENTEROCOLITIS; EVENT FREE SURVIVAL; FEVER; FLU LIKE SYNDROME; FOLLICULAR LYMPHOMA; HEMATOLOGIC DISEASE; HODGKIN DISEASE; HUMAN; INJECTION SITE REACTION; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; LUPUS LIKE SYNDROME; LYMPHATIC LEUKEMIA; LYMPHOCYTOPENIA; MALIGNANT NEOPLASM; MELANOMA; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; NEPHRITIS; NONHODGKIN LYMPHOMA; NONHUMAN; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; RESPIRATORY TRACT DISEASE; REVIEW; RHEUMATOID ARTHRITIS; SERUM SICKNESS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; SYSTEMIC VASCULITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS; TUMOR LYSIS SYNDROME; ANIMAL; CLINICAL TRIAL (TOPIC); GRAFT REJECTION; IMMUNOLOGY; NEOPLASM; PROCEDURES;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; AUTOIMMUNE DISEASES; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; GRAFT REJECTION; HUMANS; NEOPLASMS;

EID: 85051796495     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574884712666170809124728     Document Type: Review

References (66)

1. Liu JKH. The history of monoclonal antibody development-Progress, remaining challenges and future innovations. Ann Med Surg. 2014; 3(4): 113.
2. History of Monoclonal Antibodies. The Antibody Company. http://theantibodycompany.com/web/about-us/history-of-monoclonal-antibodies (Accessed Mar 26, 2017).
3. Advances in the development of therapeutic monoclonal antibodies. https://www.researchgate.net/publication/287508813_Advances_ in_the_development_of_therapeutic_monoclonal_antibodies. (Accessed Mar 26, 2017).
4. General policies for monoclonal antibodies 2009.pdf.http://www. who.int/medicines/services/inn/Generalpoliciesformonoclonalantibodies 2009.pdf. (Accessed Apr 5, 2017).
5. Orthoclone OKT3 (Muromonab CD3). https://www.drugs.com/pro/orthoclone-okt3.html (Accesses May 1, 2018).
6. RAPTIVE (Efalizumab) Label-ucm143346.pdf http://www. fda.gov/downloads/drugs/drugsafety/postmarketdrugsafetyinformat ionforpatientsandproviders/ucm143346.pdf (Accessed Dec 22, 2016).
7. BLINCYTO (Blinatumomab) Label-125557s005s006lbl.pdf. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125557s005 s006lbl.pdf (Accessed Apr 5, 2017).
8. ZEVALIN (Ibritumomab Tiuxetan) IDEC Pharmaceuticals Corp ibriide021902LB.pdf. http://www.accessdata.fda.gov/drugsatfda_ docs/label/2002/ibriide021902LB.pdf (Accessed Dec 22, 2016).
9. GAZYVATM (obinutuzumab) label-125486_s008lbl.pdf [Internet]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125486_ s008lbl.pdf (Accessed Dec 22, 2016).
10. ARZERRA (ofatumumab)-125326s062lbl.pdf. http://www. accessdata.fda.gov/drugsatfda_docs/label/2016/125326s062lbl.pdf (Accessed Dec 22, 2016).
11. RITUXAN (rituximab) Label-103705s5311lbl.pdf [Internet]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103705s531 1lbl.pdf (Accessed Dec 22, 2016).
12. BEXXAR (Tositumomab and Iodine I 131 Tositumomab) Label, Corixa Corporation-tosicor062703LB.pdf. http://www. accessdata.fda.gov/drugsatfda_docs/label/2003/tosicor062703LB. pdf (Accessed Dec 22, 2016).
13. ADCETRIS (brentuximab vedotin) Label-125388s084lbl.pdf [Internet]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125388s084lbl.pdf (Accessed Dec 22, 2016).
14. MYLOTARG (Gemtuzumab Ozogamicin) 21174lbl-21174lbl.pdf http://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21174lbl. pdf (Accessed Dec 22, 2016).
15. DARZALEX (Daratumumab) 761036Orig1s000lbledt.pdf http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761036Orig 1s000lbledt.pdf (Accessed Dec 22, 2016).
16. LEMTRADA (Alemtuzumab) 103948s5139lbl.pdf http://www. accessdata.fda.gov/drugsatfda_docs/label/2014/103948s5139lbl.pdf (Accessed Dec 22, 2016).
17. CAMPATH (Alemtuzumab) Label-103948s5150lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103948s515 0lbl.pdf (Accessed Mar 27, 2017).
18. YERVOY (ipilimumab) Label-125377s055lbl.pdf. http://www. accessdata.fda.gov/drugsatfda_docs/label/2013/125377s055lbl.pdf. (Accessed Dec 22, 2016).
19. EMPLICITI (Elotuzumab) Label-761035s000lbl.pdf. http://www. accessdata.fda.gov/drugsatfda_docs/label/2015/761035s000lbl.pdf. (Accessed Dec 22, 2016).
20. ILARIS (canakinumab) Label-125319s047lbl.pdf. http://www. accessdata.fda.gov/drugsatfda_docs/label/2012/125319s047lbl.pdf (Accessed Dec 22, 2016).
21. SIMULECT (basiliximab) Label-ucm113375.pdf. http://www. fda.gov/downloads/Drugs/DevelopmentApprovalProcess/How DrugsareDevelopedandApproved/ApprovalApplications/Therapeutic BiologicApplications/ucm113375.pdf (Accessed Dec 22, 2016).
22. ZINBRYTA (Daclizumab) Label-761029s000lbl.pdf.http://www. accessdata.fda.gov/drugsatfda_docs/label/2016/761029s000lbl.pdf (Accessed Dec 22, 2016).
23. NUCALA (Mepolizumab) Label-125526Orig1s000Lbl.pdf. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125526Orig 1s000Lbl.pdf (Accessed Dec 22, 2016).
24. CINQAIR (reslizumab) Label-761033lbl.pdf. http://www. accessdata.fda.gov/drugsatfda_docs/label/2016/761033lbl.pdf (Ac-cessed Dec 22, 2016).
25. SYLVANT (Siltuximab) Label-125496s000lbl.pdf. http://www. accessdata.fda.gov/drugsatfda_docs/label/2014/125496s000lbl.pdf (Accessed Dec 22, 2016).
26. ACTEMRA® (tocilizumab)-125276s107_125472s018lbl.pdf. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125276s107_ 125472s018lbl.pdf (Accessed Dec 22, 2016).
27. FDA Briefing Document. Dermatologic and Ophthalmic Drugs Advisory Committee Meeting; ucm511357.pdf. http://www. fda.gov/downloads/advisorycommittees/committeesmeetingmateri-als/drugs/dermatologicandophthalmicdrugsadvisorycommittee/ucm 511357.pdf (Accessed Dec 22, 2016).
28. TALTZ (Ixekizumab) Label-125521s000lbl.pdf. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125521s000 lbl.pdf (Accessed Dec 22, 2016).
29. COSENTYX (Secukinumab) Label-125504s000lbl.pdf. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125504s000 lbl.pdf (Accessed Dec 22, 2016).
30. Atopic Dermatitis-ucm439354.pdf. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/dermatologicandophthalmicdrugsadvisorycommit-tee/ucm439354.pdf (Accessed Jan 3, 2017).
31. STELARATM (Ustekinumab) Label-125261s001lbl.pdf. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125261s001 lbl.pdf (Accessed Dec 22, 2016).
32. ERBITUX (Cetuximab)-125084lbl.pdf. http://www.accessdata. fda.gov/drugsatfda_docs/label/2004/125084lbl.pdf (Accessed Dec 22, 2016).
33. PORTRAZZA (necitumumab) injection, for intravenous use-125547s000lbl.pdf. http://www.accessdata.fda.gov/drugsatfda_ docs/label/2015/125547s000lbl.pdf (Accessed Dec 22, 2016).
34. VECTIBIX (Panitumumab)-125147s0000lbl.pdf. http://www. accessdata.fda.gov/drugsatfda_docs/label/2006/125147s0000lbl.pdf (Accessed Dec 22, 2016).
35. Herceptin (trastuzumab) Label-103792s5256lbl.pdf. http://www. accessdata.fda.gov/drugsatfda_docs/label/2010/103792s5256lbl.pdf (Accessed Dec 22, 2016).
36. PERJETA® (pertuzumab) Label-125409s051lbl.pdf. http://www. accessdata.fda.gov/drugsatfda_docs/label/2013/125409s051lbl.pdf (Accessed Dec 22, 2016).
37. KADCYLA (Ado-Trastuzumab emtansine) Label-125427s033lbl. pdf. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125427s033lbl.pdf (Accessed Mar 27, 2017).
38. LARTRUVO (Olaratumab) Label-761038lbl.pdf. http://www. accessdata.fda.gov/drugsatfda_docs/label/2016/761038lbl.pdf (Accessed Dec 22, 2016).
39. AVASTIN (Bevacizumab) 125085s301lbl.pdf. http://www. accessdata.fda.gov/drugsatfda_docs/label/2014/125085s301lbl.pdf (Accessed Dec 22, 2016).
40. LUCENTIS (ranibizumab injection) label-125156s105lbl.pdf. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125156s105 lbl.pdf (Accessed Dec 22, 2016).
41. CYRAMZA (ramucirumab) injection Label-125477s002lbl.pdf. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125477s002 lbl.pdf (Accessed Dec 22, 2016).
42. HUMIRA (adalimumab) label-125057s0276lbl.pdf http://www. accessdata.fda.gov/drugsatfda_docs/label/2011/125057s0276lbl.pdf (Accessed Dec 22, 2016).
43. CIMZIA (Certolizumab) Label-125160s111lbl.pdf. http://www. accessdata.fda.gov/drugsatfda_docs/label/2010/125160s111lbl.pdf (Accessed Dec 22, 2016).
44. SIMPONI (golimumab) label-125289s0064lbl.pdf. http://www. accessdata.fda.gov/drugsatfda_docs/label/2011/125289s0064lbl.pdf (Accessed Dec 22, 2016).
45. REMICADE (infliximab) Label-103772s5359lbl.pdf. http://www. accessdata.fda.gov/drugsatfda_docs/label/2013/103772s5359lbl.pdf (Accessed Dec 22, 2016).
46. XGEVA (denosumab) Label-125320s094lbl.pdf. http://www. accessdata.fda.gov/drugsatfda_docs/label/2013/125320s094lbl.pdf (Accessed Dec 22, 2016).
47. ZINPLAVA (Bezlotoxumab) Label-761046s000lbl.pdf. http://www. accessdata.fda.gov/drugsatfda_docs/label/2016/761046s000lbl.pdf (Accessed Dec 22, 2016).
48. ANTHIM (obiltoxaximab) injection-125509lbl.pdf.http://www. accessdata.fda.gov/drugsatfda_docs/label/2016/125509lbl.pdf (Accessed Dec 22, 2016).
49. SYNAGIS (Palivizumab) Label-palimed102302LB.pdf. http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/palimed102 302LB.pdf(Accessed Dec 22, 2016).
50. Raxibacumab-125349s000lbl.pdf. http://www.accessdata. fda.gov/drugsatfda_docs/label/2012/125349s000lbl.pdf (Accessed Dec 22, 2016).
51. BAVENCIO (Avelumab) Label-761049s000lbl.pdf. https://www. accessdata.fda.gov/drugsatfda_docs/label/2017/761049s000lbl.pdf (Accessed Apr 5, 2017).
52. OPDIVO (nivolumab) injection Label-125554lbl.pdf. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125554lbl.pdf (Accessed Dec 22, 2016).
53. KEYTRUDA (Pembrolizumab) Label-125514s004s006lbl.pdf. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125514s004 s006lbl.pdf (Accessed Dec 22, 2016).
54. PRALUENT (Alirocumab) Label-125559Orig1s000lbledt.pdf. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125559Orig 1s000lbledt.pdf (Accessed Dec 22, 2016).
55. REPATHA (Evolocumab) Label-125522s000lbl.pdf. http://www. accessdata.fda.gov/drugsatfda_docs/label/2015/125522s000lbl.pdf (Accessed Dec 22, 2016).
56. TYSABRI (natalizumab) Label-125104lbl.pdf. http://www. accessdata.fda.gov/drugsatfda_docs/label/2004/125104lbl.pdf (Accessed Dec 22, 2016).
57. ENTYVIO (Vedolizumab) Label-125476s000lbl.pdf. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125476s000 lbl.pdf (Accessed Dec 22, 2016).
58. XOLAIR (Omalizumab) LABEL-103976s5225lbl.pdf. http://www. accessdata.fda.gov/drugsatfda_docs/label/2016/103976s5225lbl.pdf (Accessed Dec 22, 2016).
59. SOLIRIS (eculizumab)-125166lbl.pdf. http://www.accessdata. fda.gov/drugsatfda_docs/label/2007/125166lbl.pdf (Accessed Dec 22, 2016).
60. BENLYSTA® (belimumab) Label-125370s016lbl.pdf. http://www. accessdata.fda.gov/drugsatfda_docs/label/2012/125370s016lbl.pdf (Accessed Dec 22, 2016).
61. Abciximab-ucm107731.pdf. https://www.accessdata.fda. gov/drugsatfda_docs/label/1997/abcicen110597-lab.pdf (Accessed Dec 22, 2016).
62. PRAXBIND (idarucizumab) injection, for intravenous use-761025lbl.pdf. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761025lbl.pdf (Accessed Dec 22, 2016).
63. UNITUXIN (Dinutuximab) Label-125516s000lbl.pdf. http://www. accessdata.fda.gov/drugsatfda_docs/label/2015/125516s000lbl.pdf (Accessed Dec 22, 2016).
64. Pullen LC [2010, August 31] Catumaxomab Effective in Treating Malignant Ascites. Medscape. http://www.medscape.com/viewarticle/727766 (Accessed Jan 3, 2017).
65. The safety and side effects of monoclonal antibodies – Therapeutic Review2010.pdf. http://theory.bio.uu.nl/immbio/pdf/Therapeutic Review2010.pdf (Accessed Apr 5, 2017).
66. Kaur R, Sidhu P, Singh S. What failed BIA 10-2474 Phase I clinical trial? Global speculations and recommendations for future Phase I trials. J Pharmacol Pharmacother 2016; 7(3): 120-6.